The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 11, 2025

Filed:

Feb. 12, 2019
Applicant:

Checkmate Pharmaceuticals, Inc., Cambridge, MA (US);

Inventors:

Arthur Krieg, Cambridge, MA (US);

Aaron Morris, Brighton, MA (US);

David Mauro, Washington Crossing, PA (US);

George Weiner, Iowa City, IA (US);

Mohammed Milhem, Iowa City, IA (US);

Assignee:

CHECKMATE PHARMACEUTICALS, INC., Cambridge, MA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/7125 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/7125 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); A61K 2039/505 (2013.01); A61K 45/06 (2013.01);
Abstract

Provided are compositions and methods for treating cancer using administration of certain volumes of CpG oligonucleotides (CpG ODN) and, optionally, administration of a checkpoint inhibitor such as an anti-PD-1 antibody, an anti-PD-L1 antibody, and/or an anti-CTLA-4 antibody. In preferred embodiments, the CpG ODN are selected based on their propensity to induce high amounts of interferon alpha (IFN-a) and T-cell activation relative to interleukin-10 (IL-10) and B-cell activation. In certain embodiments, the methods further include pretreatment with radiotherapy, to potentiate the combination immunotherapy.


Find Patent Forward Citations

Loading…